Tissue plasminogen activator (tPA), which is a thrombolytic agent, is currently the only drug approved by the U.S. Food and Drug Administration for treating cerebral infarction, and should be administered within 3 h of the onset of acute cerebral infarction [7]. This evidence concerns the gene PLAT and cerebral infarction.